StockData

Lifevantage vs Niagen Bioscience

LFVN and NAGE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LFVN and NAGE compare

Niagen Bioscience is the larger company, worth 2.7 times as much as Lifevantage ($161M against $59.9M).

On earnings, Lifevantage is cheaper: it trades at 11.9× trailing earnings, against 17.0× for Niagen Bioscience.

Niagen Bioscience grew revenue faster over the last twelve months (−1.9% versus −20.1% for Lifevantage).

Niagen Bioscience keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with 2.8% at Lifevantage.

Lifevantage pays a dividend yielding 4.0%; Niagen Bioscience does not pay one.

Lifevantage scores higher on the StockData Score (20 against 14 for Niagen Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLFVNNAGE
Size and price
Market cap$59.9M$161M
Share price$4.78$2.04
Change, 1 year−27.8%−70.3%
Change, 5 years−29.2%−58.5%
Beta (5Y)0.591.06
Employees223117
StockData Score
Total score20 (better)14
Valuation score6 (better)3
Growth score11
Performance score44
Health score56 (better)
Dividend score4 (better)0
Valuation
P/E11.9× (better)17.0×
P/S0.3× (better)1.3×
P/B1.8× (better)1.9×
EV/EBITDA5.1× (better)19.2×
P/FCF9.0×–
PEG0.46–
FCF yield11.1%–
Fair value$8.48$2.30
Margin of safety43.6% (better)11.1%
Growth
Revenue growth (TTM)−20.1%−1.9% (better)
Revenue growth, 5Y average−3.7%16.9% (better)
Net income growth (TTM)−48.3% (better)−49.9%
EPS growth (TTM)−46.7% (better)−50.0%
EPS growth, 5Y average−15.0%–
Profitability
Gross margin77.6% (better)63.9%
Operating margin3.3%3.9% (better)
Net margin2.8%8.4% (better)
FCF margin3.7%–
Return on equity14.9% (better)13.3%
Return on invested capital30.8%44.3% (better)
Financial health
Debt / equity0.000.00
Current ratio1.895.93 (better)
Altman Z-score2.543.93 (better)
Piotroski F-score67 (better)
Dividends and buybacks
Dividend yield4.0%–
Payout ratio46.2%–
Years of dividend growth1–
Buyback yield3.4% (better)3.3%
Shareholder yield7.4% (better)3.3%
Ownership
Held by institutions47.2%40.4%
Held by insiders27.8%5.1%
Insider net buying, 12 months$6.0K (better)$0
Short interest, % of float10.0%5.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.